MARIETTA,Solvay Pharmaceuticals’ new drug application has received priority review from the Food and Drug Administration for its proposed treatment of irritable bowel syndrome with diarrhea.
The illness affects between 30-45 million men and women in North America.
The drug is called cilansetron. It has been tested so far on 4,000 patients worldwide.
Priority review is granted by the FDA to drugs that appear to be a potential advance beyond existing therapies.
Solvay: www.solvaypharmaceuticals-us.com
